Movement Alert｜Hengrui Medicine Rises 3.44% in Regular Trading, Stabilizing Rebound After Post-BMS Cooperation Pullback

Market Focus

May 21

On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.

The rebound comes after the stock experienced a cumulative decline exceeding 10% following a major partnership announcement. On May 12, Hengrui announced a global strategic cooperation and licensing agreement with Bristol-Myers Squibb to jointly advance 13 early-stage innovative projects spanning oncology, hematology, and immunology, with a potential total deal value of approximately US$15.2 billion including a US$600 million upfront payment. The stock surged over 16% on the announcement day but faced sustained profit-taking in subsequent sessions.

Sector-wide strength provided additional support, with Asymchem surging 9.09% and HUTCHMED gaining 1.38% within the Pharmaceuticals sector. Institutional interest remains strong, with Schroders PLC having increased its stake by 663,000 shares at approximately HK$68.70 per share on May 12, bringing its holding to 5.1%. The company also announced a dividend of RMB 0.2 per share with a record date of May 26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1134571193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134571193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134571193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 13:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134571193","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.44% in Regular Trading, Stabilizing Rebound After Post-BMS Cooperation Pullback","media":"Market Focus","content":"<p><p>On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.</p><p>The rebound comes after the stock experienced a cumulative decline exceeding 10% following a major partnership announcement. On May 12, Hengrui announced a global strategic cooperation and licensing agreement with Bristol-Myers Squibb to jointly advance 13 early-stage innovative projects spanning oncology, hematology, and immunology, with a potential total deal value of approximately US$15.2 billion including a US$600 million upfront payment. The stock surged over 16% on the announcement day but faced sustained profit-taking in subsequent sessions.</p><p>Sector-wide strength provided additional support, with Asymchem surging 9.09% and HUTCHMED gaining 1.38% within the Pharmaceuticals sector. Institutional interest remains strong, with Schroders PLC having increased its stake by 663,000 shares at approximately HK$68.70 per share on May 12, bringing its holding to 5.1%. The company also announced a dividend of RMB 0.2 per share with a record date of May 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.44% in Regular Trading, Stabilizing Rebound After Post-BMS Cooperation Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.44% in Regular Trading, Stabilizing Rebound After Post-BMS Cooperation Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 13:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.</p><p>The rebound comes after the stock experienced a cumulative decline exceeding 10% following a major partnership announcement. On May 12, Hengrui announced a global strategic cooperation and licensing agreement with Bristol-Myers Squibb to jointly advance 13 early-stage innovative projects spanning oncology, hematology, and immunology, with a potential total deal value of approximately US$15.2 billion including a US$600 million upfront payment. The stock surged over 16% on the announcement day but faced sustained profit-taking in subsequent sessions.</p><p>Sector-wide strength provided additional support, with Asymchem surging 9.09% and HUTCHMED gaining 1.38% within the Pharmaceuticals sector. Institutional interest remains strong, with Schroders PLC having increased its stake by 663,000 shares at approximately HK$68.70 per share on May 12, bringing its holding to 5.1%. The company also announced a dividend of RMB 0.2 per share with a record date of May 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1134571193","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134571193","pubTimestamp":1779340230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.The rebound comes after the stock experienced a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动向提示|恒瑞医药常规盘涨3.44%BMS合作后回调企稳反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.The rebound comes after the stock experienced a cumulative decline exceeding 10% following a major partnership announcement. On May 12, Hengrui announced a global strategic cooperation and licensing agreement with Bristol-Myers Squibb to jointly advance 13 early-stage innovative projects spanning oncology, hematology, and immunology, with a potential total deal value of approximately US$15.2 billion including a US$600 million upfront payment. The stock surged over 16% on the announcement day but faced sustained profit-taking in subsequent sessions.Sector-wide strength provided additional support, with Asymchem surging 9.09% and HUTCHMED gaining 1.38% within the Pharmaceuticals sector. Institutional interest remains strong, with Schroders PLC having increased its stake by 663,000 shares at approximately HK$68.70 per share on May 12, bringing its holding to 5.1%. The company also announced a dividend of RMB 0.2 per share with a record date of May 26.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}